Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masurasavir (GP681) dry suspension in children with uncomplicated influenza
CTR20252773Phase 3Completed
- Sponsor
- Qingfeng Pharmaceutical Group
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of suraxavir marboxil in Influenza A infection, influenza B, sponsored by Qingfeng Pharmaceutical Group. Started Jul 2025; status: completed.
02
Drugs
suraxavir marboxil
03
Conditions
Influenza A infectioninfluenza B
Beyond the preview
Go deeper on CTR20252773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252773.